During a panel discussion at HLTH, Chelsea Clinton shared three things she wants healthcare leaders to know going into the election when it comes to reproductive health. The post Chelsea Clinton on Reproductive Rights: 3 Things to Know appeared first on MedCity News.
Avandra Imaging, a federated network for de-identified imaging data, emerged from stealth at HLTH — as well as announced a partnership with Datavant. The post Avandra Imaging Emerges from Stealth to Solve a Last-Mile Problem in Medical Research appeared first on MedCity News.
Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
Both providers and payers face challenges and understanding the requirements and needs of each stakeholder has the potential to lower the temperature of the current rhetoric. The post Analyzing the Medicare Advantage Terminations: Concerns, Drivers, and Solutions appeared first on MedCity News.
Highly preventable if diagnosed and managed early, CAD should be a healthcare priority. Both patients and providers have pivotal roles in driving this change. The post The Case for Prioritizing the Number One Killer: Cardiovascular Disease appeared first on MedCity News.
Recent failures in the retail health space beg the question: Is primary care only suited to remain within traditional players? Four healthcare executives shared their responses to this question during a panel at HLTH in Las Vegas. The post Can Primary Care Thrive Outside of Traditional Healthcare Players? appeared first on MedCity News.
During HLTH 2024, Blue Shield of California and Salesforce announced a partnership that will streamline the prior authorization process. The post Blue Shield of California, Salesforce Partner to Modernize Prior Authorization appeared first on MedCity News.
The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2. It’s the first FDA-approved therapy for this target. The post Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer appeared first on MedCity News.
Within a matter of months, we’re likely to see substantial growth in the number of EP ablation procedures performed in surgery centers outside the hospital. Here’s what we can expect. The post How the Move of Ablation Procedures into Surgery Centers Will Transform Electrophysiology appeared first on MedCity News.
Closing cancer health equity gaps requires medical breakthroughs made possible by new funding approaches. The post The Funding Model for Cancer Innovation is Broken — We Can Fix It appeared first on MedCity News.